#antibiotic-pipeline-financing

Scientific risk, weak commercial returns and unequal market access leave too few innovative antibiotics for priority resistant pathogens and limit delivery after approval.

Develop regulated phage libraries, rapid bacterial matching, stable manufacturing, and adaptive treatment protocols for infections that lack effective antibiotic options.

Prioritize antibiotics with new targets or mechanisms against critical resistant pathogens and plan registration, manufacturing, supply and stewardship across income settings before approval.

Provide grants and milestone payments for high-priority antibiotics, diagnostics and nontraditional products while attaching stewardship, access and data-sharing conditions.

Pay suppliers predictable amounts for the availability and public-health value of priority antibiotics rather than rewarding the number of doses sold.

PhagoBurn was a randomized, controlled phase 1/2 trial comparing a topical anti-Pseudomonas aeruginosa phage cocktail with standard care for infected burn wounds, conducted across multiple European burn units. Manufactu…

NHS England and NICE piloted fixed annual payments for access to cefiderocol and ceftazidime-avibactam, with value assessment designed to recognize preparedness and public-health benefits rather than prescription volume…